Third generation cephalosporin-resistant Klebsiella pneumoniae thriving in patients and in wastewater: what do they have in common?

BMC Genomics

Universidade Católica Portuguesa, CBQF - Centro de Biotecnologia e Química Fina - Laboratório Associado, Escola Superior de Biotecnologia, Rua Diogo Botelho 1327, 4169-005, Porto, Portugal.

Published: January 2022

Background: Klebsiella pneumoniae are ubiquitous bacteria and recognized multidrug-resistant opportunistic pathogens that can be released into the environment, mainly through sewage, where they can survive even after wastewater treatment. A major question is if once released into wastewater, the selection of lineages missing clinically-relevant traits may occur. Wastewater (n = 25) and clinical (n = 34) 3 generation cephalosporin-resistant K. pneumoniae isolates were compared based on phenotypic, genotypic and genomic analyses.

Results: Clinical and wastewater isolates were indistinguishable based on phenotypic and genotypic characterization. The analysis of whole genome sequences of 22 isolates showed that antibiotic and metal resistance or virulence genes, were associated with mobile genetic elements, mostly transposons, insertion sequences or integrative and conjugative elements. These features were variable among isolates, according to the respective genetic lineage rather than the origin.

Conclusions: It is suggested that once acquired, clinically relevant features of K. pneumoniae may be preserved in wastewater, even after treatment. This evidence highlights the high capacity of K. pneumoniae for spreading through wastewater, enhancing the risks of transmission back to humans.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783465PMC
http://dx.doi.org/10.1186/s12864-021-08279-6DOI Listing

Publication Analysis

Top Keywords

generation cephalosporin-resistant
8
klebsiella pneumoniae
8
wastewater treatment
8
based phenotypic
8
phenotypic genotypic
8
wastewater
7
pneumoniae
5
third generation
4
cephalosporin-resistant klebsiella
4
pneumoniae thriving
4

Similar Publications

Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates.

View Article and Find Full Text PDF

Retrospective Analysis of Ceftriaxone 1 Gram or 2 Grams for Bacteremia.

J Pharm Pract

January 2025

Emergency Medicine, Department of Pharmacy, Long Island Jewish Valley Stream, Valley Stream, NY, USA.

Ceftriaxone is a third-generation cephalosporin commonly used for treating bacteremia caused by gram-positive organisms such as and gram-negative organisms such as Enterobacterales. The typical doses for treating bacteremia are either 1 gram or 2 grams daily. Despite its widespread use, there are limited data on the optimal treatment dose for bacteremia.

View Article and Find Full Text PDF

Background And Objectives: The incidence of multidrug-resistant, Gram-negative organisms, isolated as the etiological agents of infections is ascending. The advent of novel antibiotics poses significant challenges, necessitating the optimization and utilization of extant antimicrobial agents. Cefoperazone, a third-generation cephalosporin and β-lactam antimicrobial, when combined with sulbactam, an irreversible β-lactamase inhibitor, mitigates the vulnerability of cefoperazone to β-lactamase-producing organisms.

View Article and Find Full Text PDF

Understanding the impact of antibiotics on bacterial metabolism is crucial for elucidating their mechanisms of action and developing more effective therapeutic strategies. β-lactam antibiotics, distinguished by their distinctive β-lactam ring structure, are widely used as antimicrobial agents. This study investigates the global metabolic alterations induced by three β-lactam antibiotics-meropenem (a carbapenem), ampicillin (a penicillin), and ceftazidime (a cephalosporin)-in .

View Article and Find Full Text PDF

Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime?

J Antimicrob Chemother

December 2024

Infectious Diseases Unit, CHU de La Réunion, Saint-Pierre, La Réunion, 97410, France.

Introduction: Temocillin is a semi-synthetic β-lactam with a narrow spectrum but high stability against hydrolysis by β-lactamases, including AmpC. Despite its favourable properties, data regarding its clinical value in the treatment of AmpC β-lactamase-producing Enterobacterales (ABPE) infections are scarce. Most recent guidelines do not include temocillin in the therapeutic strategy for ABPE infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!